Sanofi pegs U.S. drug price rises to below healthcare inflation

(Reuters) - French drugmaker Sanofi has pledged to peg U.S. drug price rises to below healthcare inflation in a move that limits increases for any product this year to 5.4 percent, unless there are exceptional circumstances.